2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1098

Epidemiology and Mortality of SLE (Systemic Lupus Erythematosus) in Hungary Based on a Nationwide Retrospective Claims Database Study
Abstract Number: 908

Epidemiology and Presentation of Sarcoidosis with and Without HIV Infection
Abstract Number: 2054

Epidemiology of Gout in South Korea with the National Health Insurance Corporation Database
Abstract Number: 187

Epidemiology of JIA-Associated Uveitis: Environmental Factors and Disease Characteristics of a JIA-Associated Uveitis Cohort
Abstract Number: 2349

Epidemiology, Risk/Prognostic Factors, and Treatment Landscape in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Systematic Literature Review
Abstract Number: 1267

Epidemology, Clinical Features and Relationship to Biological Therapy of Uveitis in Axial Spondyloarthritis: Single Center University Study
Abstract Number: 1074

Epigenetic Regulation-Mediated Reduction in the Expression of Prostacyclin Receptor and Prostacyclin Synthase in Scleroderma Skin, Vascular Smooth Muscle Cells, and Microvascular Endothelial Cells
Abstract Number: 2041

Epigenome-wide Association Study Reveals Differential DNA Methylation in Systemic Lupus Erythematosus Patients with a History of Ischemic Heart Disease
Abstract Number: 1029

Epstein-Barr Virus Interleukin 10 in SLE Pathogenesis
Abstract Number: 1163

Erosions Are the Most Often Reported Structural Lesion on MRI of the Sacroiliac Joints in axSpA Patients with IBP
Abstract Number: 2179

Erosive Hand Osteoarthritis, Metabolic Syndrome and Knee Osteoarthritis: A Cross-sectional Study Using Data from the PROCOAC Cohort
Abstract Number: 1654

Esophageal Dilation and Other Clinical Factors Associated with Pulmonary Function Decline in Patients with Systemic Sclerosis
Abstract Number: 1988

Establishing an in Vitro Model of Hand Osteoarthritis by Generating Induced Pluripotent Stem Cells (iPSc) That Carry Single Nucleotide Polymorphisms Associated with Hand Osteoarthritis Risk
Abstract Number: 1102

Estimate of Prevalence of Secondary Distal Renal Tubular Acidosis Among Patients with Sjogren’s Syndrome and Systemic Lupus Erythematosus in a US Population with Employer-Sponsored Health Insurance
Abstract Number: 1953

Estimating the Infiltration of Immune Cells in Synovium of Rheumatoid Arthritis Compared to Osteoarthritis and Healthy Control Using Transcriptomic Profiling

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].